A tentative green light from the United States drug regulator has moved Alembic Pharmaceuticals and its partner NATCO Pharma a step closer to selling a low-cost copy of one of AstraZeneca's best-selling cancer therapies in the American market.
What Was Approved
NATCO Pharma has received tentative approval from the US Food and Drug Administration for its abbreviated new drug application covering Olaparib Tablets in 100 mg and 150 mg strengths. Alembic Pharmaceuticals disclosed the development, noting that the clearance covers the same disease indication listed on the label of the original branded drug. Under the arrangement between the two companies, NATCO Pharma will handle manufacturing of the tablets while Alembic Pharmaceuticals takes charge of distributing the product across the United States once it reaches the market.
A Market Worth Roughly $1.4 Billion
Olaparib in the 100 mg and 150 mg doses is not a small niche product. Citing IQVIA data, the company pointed to an estimated market size of around USD 1.4 billion in the US for the twelve months ending March 2026, underlining why securing a foothold in this segment matters for both partners' revenue plans.
Litigation Still Stands In The Way
Regulatory clearance, however, does not automatically translate into shelf availability. The two firms have flagged that the actual launch date hinges on how an ongoing Paragraph IV patent dispute over the product plays out, meaning this tentative nod is best read as a milestone rather than a starting gun for sales. Olaparib itself belongs to a class of medicines called PARP inhibitors, prescribed for certain forms of cancer, and is sold under the brand name Lynparza by AstraZeneca.
Alembic's Growing US Approval Tally
With this clearance, Alembic Pharmaceuticals' running count of ANDA approvals from the US drug regulator has climbed to 244, made up of 224 final approvals and 20 tentative ones. The company describes itself as a vertically integrated, research-driven pharmaceutical business active in both generic medicines and branded generics, running manufacturing and research sites that carry approvals from regulators in developed markets, including the US drug regulator.
Part Of A Wider Push By Indian Drugmakers
The development lands at a time when Indian pharmaceutical firms are increasingly chasing complex, high-value generic opportunities in the United States through tie-ups like this one. For Alembic, the tentative nod opens up another potential revenue stream, though how soon it converts into actual sales will depend on the outcome of the pending litigation and the timing of a commercial launch.
